Actively Recruiting
Improving Overactive Bladder Treatment Access and Adherence
Led by Stanford University · Updated on 2025-11-26
30
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
Sponsors
S
Stanford University
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Overactive bladder (OAB) and urinary incontinence (UI) are chronic debilitating and embarrassing conditions that affect 33 million Americans. Yet, both are underdiagnosed and undertreated with significant financial and health-related consequences. OAB syndrome is characterized by urinary urgency, with and without urinary incontinence, urinary frequency, and nocturia. Evidence-based treatments are available, including behavioral therapy, pharmacotherapy, and minimally invasive procedures. Diagnosis and treatment are also associated with improvement in urinary symptoms and overall quality of life (QOL).3 However, 70-80% of treated patients will discontinue use of therapy in the first year due to one of several factors (e.g., cost, tolerability, inadequate effect). In addition, only 4.7% progress to advanced therapies suggesting undertreatment for those that need it most. Vulnerable populations are especially at risk, as therapy utilization are lowest among older, lower income, and/or minority groups. Poor access, insufficient patient education regarding disease chronicity, expected outcomes, costs, and potential side effects lead to unrealistic patient perceptions about therapy. This leads to suboptimal therapy duration, poor treatment efficacy, adherence, and undertreatment. The study aims to evaluate a tailored patient-centered tool to begin the treatment process.
CONDITIONS
Official Title
Improving Overactive Bladder Treatment Access and Adherence
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female aged 18 years or older
- Overactive bladder symptoms for at least 3 months
- English or Spanish language skills and cognitive ability to complete study materials
- Patients who have not previously received behavioral treatment for OAB
- Patients previously treated for OAB but without supervised pelvic floor physical therapy or pharmacotherapy in the past year
You will not qualify if you...
- Post void residual urine greater than 150 ml
- Diagnosis of Interstitial Cystitis/Painful Bladder Syndrome
- Pregnant or breastfeeding
- Living in a nursing home
- Neurological conditions such as spinal cord injury, Multiple Sclerosis, Parkinson's disease, brain tumor, or stroke
- Stage 2 or greater pelvic organ prolapse
- History of urethral stricture
- History of pelvic irradiation
- History of bladder cancer
- Current symptomatic urinary tract infection not resolved at enrollment
- Hematuria without clinical evaluation
- History or current use of indwelling urinary catheters or intermittent catheterization
- Patients treated with onabotulinumtoxinA, sacral neuromodulation, or percutaneous tibial nerve stimulation for urinary incontinence
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Stanford Pelvic Health Center
Redwood City, California, United States, 94062
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here